文献速递肝病消化道肿瘤与早癌

美国肝硬化退伍军人中肝细胞癌治疗相关的医疗费用

Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-07-26

该研究基于退伍军人事务部队列,匹配分析3188例肝细胞癌患者与12722例肝硬化对照,发现肝细胞癌患者3年总费用为154688美元,对照为69010美元,增量费用85679美元,其中64.9%为住院费用增加。肝移植、BCLC分期和多学科肿瘤委员会与费用相关,基于这些变量建立的模型能准确预测费用。

要点

  • 肝细胞癌患者3年总费用为154688美元,匹配肝硬化对照为69010美元,增量费用85679美元。
  • 增量费用的64.9%反映为住院费用增加。
  • 肝移植、BCLC分期和多学科肿瘤委员会与肝细胞癌相关费用独立相关。

核心结论

  • 在综合医疗系统中,肝移植、BCLC分期和多学科肿瘤委员会与肝硬化患者肝细胞癌的较高医疗费用相关。
  • 基于肝移植状态等变量构建的模型可预测总费用,并可用于肝细胞癌预防治疗的成本效果建模。

研究设计与样本

  • 研究基于退伍军人结局与肝病相关费用队列,纳入2008-2010年确诊的3188例肝细胞癌患者和12722例匹配的肝硬化对照(1:4匹配,基于肝病严重程度、年龄和合并症)。
  • 使用退伍军人事务部企业数据仓库汇总诊断后3年的费用,并建立单变量和多变量广义线性模型预测癌症相关总费用。

主要发现

  • 肝细胞癌患者3年总费用均值为154688美元(标准误范围150953-158422美元),匹配肝硬化对照为69010美元(标准误范围67344-70675美元),增量费用为85679美元。
  • 增量费用的64.9%反映为住院费用增加。
  • 单变量分析中,接受移植、BCLC分期、肝病病因、医院学术隶属、多学科肿瘤委员会使用和通过监测发现与癌症相关费用相关。
  • 多变量广义线性模型纳入移植状态、BCLC分期和多学科肿瘤委员会能准确预测肝癌相关费用(Hosmer-Lemeshow拟合优度检验;P值约等于1.0)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: It is important to quantify medical costs associated with hepatocellular carcinoma (HCC), the incidence of which is rapidly increasing in the United States, for development of rational healthcare policies related to liver cancer surveillance and treatment of chronic liver disease. We aimed to comprehensively quantify healthcare costs for HCC among patients with cirrhosis in an integrated health system and develop a model for predicting costs that is based on clinically relevant variables. METHODS: Three years subsequent to liver cancer diagnosis, costs accrued by patients included in the Veteran's Outcome and Cost Associated with Liver disease cohort were compiled by using the Department of Veterans Affairs Corporate Data Warehouse. The cohort includes all patients with HCC diagnosed in 2008-2010 within the VA with 100% chart confirmation as well as chart abstraction of tumor and clinical characteristics. Cancer cases were matched 1:4 with non-cancer cirrhosis controls on the basis of severity of liver disease, age, and comorbidities to estimate background cirrhosis-related costs. Univariable and multivariable generalized linear models were developed and used to predict cancer-related overall cost. RESULTS: Our analysis included 3188 cases of HCC and 12,722 controls. The mean 3-year total cost of care in HCC patients was $154,688 (standard error, $150,953-$158,422) compared with $69,010 (standard error, $67,344-$70,675) in matched cirrhotic controls, yielding an incremental cost of $85,679; 64.9% of this value reflected increased inpatient costs. In univariable analyses, receipt of transplantation, Barcelona Clinic Liver Cancer (BCLC) stage, liver disease etiology, hospital academic affiliation, use of multidisciplinary tumor board, and identification through surveillance were associated with cancer-related costs. Multivariable generalized linear models incorporating transplantation status, BCLC stage, and multidisciplinary tumor board presentation accurately predicted liver cancer-related costs (Hosmer-Lemeshow goodness of fit; P value ≅ 1.0). CONCLUSIONS: In a model developed to comprehensively quantify healthcare costs for HCC among patients with cirrhosis in an integrated health system, we associated receipt of liver transplantation, BCLC stage, and multidisciplinary tumor board with higher costs. Models that predict total costs on the basis of receipt of liver transplantation were constructed and can be used to model cost-effectiveness of therapies focused on HCC prevention.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kaplan DE, Chapko MK, Mehta R, et al. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2017. PMID: 28756056. doi:10.1016/j.cgh.2017.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。